AU2020363354A1 - Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers - Google Patents

Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers Download PDF

Info

Publication number
AU2020363354A1
AU2020363354A1 AU2020363354A AU2020363354A AU2020363354A1 AU 2020363354 A1 AU2020363354 A1 AU 2020363354A1 AU 2020363354 A AU2020363354 A AU 2020363354A AU 2020363354 A AU2020363354 A AU 2020363354A AU 2020363354 A1 AU2020363354 A1 AU 2020363354A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
cycloalkyl
heterocycle
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020363354A
Other languages
English (en)
Inventor
Fabrizio Giordanetto
Morten Østergaard Jensen
Vishwanath JOGINI
Roger John Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DE Shaw Research LLC
Original Assignee
DE Shaw Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DE Shaw Research LLC filed Critical DE Shaw Research LLC
Publication of AU2020363354A1 publication Critical patent/AU2020363354A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AU2020363354A 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers Abandoned AU2020363354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911642P 2019-10-07 2019-10-07
US62/911,642 2019-10-07
PCT/US2020/054348 WO2021071803A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (1)

Publication Number Publication Date
AU2020363354A1 true AU2020363354A1 (en) 2022-04-21

Family

ID=75436850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020363354A Abandoned AU2020363354A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers

Country Status (11)

Country Link
US (1) US20230040182A1 (https=)
EP (1) EP4041408A4 (https=)
JP (1) JP7780439B2 (https=)
KR (1) KR20220079575A (https=)
CN (1) CN114728177B (https=)
AU (1) AU2020363354A1 (https=)
BR (1) BR112022006250A2 (https=)
CA (1) CA3156981C (https=)
IL (1) IL291867A (https=)
MX (1) MX2022004144A (https=)
WO (1) WO2021071803A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003841A (es) 2020-10-06 2023-06-23 De Shaw Res Llc Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3.
CN114437070A (zh) * 2022-01-19 2022-05-06 广西-东盟食品检验检测中心 一种他达拉非新型衍生物的制备方法
WO2024088343A1 (zh) * 2022-10-28 2024-05-02 上海深势唯思科技有限责任公司 一种芳基杂环类Kv1.3抑制剂及其制备方法和用途
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2026021011A1 (zh) * 2024-07-26 2026-01-29 浙江海正药业股份有限公司 芳基三环类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007052A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
WO2005030729A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
CN100530013C (zh) * 2005-03-04 2009-08-19 松下电器产业株式会社 电子设备控制装置及其控制方法
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2011073273A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
US20120065210A1 (en) * 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
TWI698438B (zh) * 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Also Published As

Publication number Publication date
EP4041408A1 (en) 2022-08-17
CA3156981C (en) 2025-06-17
IL291867A (en) 2022-06-01
WO2021071803A1 (en) 2021-04-15
JP2022550641A (ja) 2022-12-02
JP7780439B2 (ja) 2025-12-04
KR20220079575A (ko) 2022-06-13
CA3156981A1 (en) 2021-04-15
US20230040182A1 (en) 2023-02-09
EP4041408A4 (en) 2023-10-18
MX2022004144A (es) 2022-06-14
CN114728177B (zh) 2025-06-24
BR112022006250A2 (pt) 2022-06-21
CN114728177A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
JP7780439B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
AU2020362108A1 (en) Aryl heterocyclic compounds as Kv1.3 potassium shaker channel blockers
CA3157026A1 (en) Arylmethylene aromatic compounds as kv1.3 potassium shaker channel blockers
AU2021358700A1 (en) LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
CA3219345A1 (en) Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
JP7780440B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
JP7822940B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
JP2025131590A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
EA046803B1 (ru) АРИЛЬНЫЕ ГЕТЕРОБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК БЛОКАТОРЫ КАЛИЕВОГО КАНАЛА Kv1.3 ТИПА SHAKER

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period